Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16341433 | 1.00 | PTGER4 (0.62) | PTGER4CNR1CNR2P2RX4ALOX15 | |
| SCHEMBL22416146 | 1.00 | PTGER4 (0.62) | PTGER4CNR1CNR2P2RX4ALOX15 | |
| SCHEMBL16341447 | 0.90 | PTGER4 (0.60) | PTGER4CNR1CNR2P2RX4ALOX15 | |
| SCHEMBL16341681 | 0.89 | PTGER4 (0.62) | PTGER4CNR1CNR2P2RX4ALOX15 | |
| SCHEMBL16341822 | 0.86 | PTGER4 (0.64) | PTGER4CNR1CNR2P2RX4ALOX15 | |
| SCHEMBL16341676 | 0.84 | PTGER4 (0.62) | PTGER4CNR1CNR2P2RX4ALOX15 | |
| SCHEMBL16341426 | 0.84 | PTGER4 (0.62) | PTGER4CNR1CNR2P2RX4ALOX15 | |
| SCHEMBL16341865 | 0.83 | PTGER4 (0.66) | PTGER4CNR1CNR2P2RX4CHRM1 | |
| SCHEMBL16340925 | 0.82 | PTGER4 (0.63) | PTGER4CNR1CNR2P2RX4CHRM1 | |
| SCHEMBL1219481 | 0.80 | PTGER4 (0.88) | PTGER4CNR1CNR2ALOX15L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2821401-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | Takeda Pharmaceutical Company Limited (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2821401-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | Takeda Pharmaceutical Company Limited (JP) | 2015-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | CHRM1, CHRM4, CHRM2 | PTGER4 629/4885CNR1 13/4885CNR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.